Investors / United Kingdom / Norcliffe Capital
Norcliffe Capital
Venture capital · London, United Kingdom · Europe
Norcliffe Capital is a UK-based investment firm that provides direct investment in medical technology and biotechnology companies, offering tax-efficient EIS and SEIS investments to high-net-worth investors. It supports portfolio companies with its team's life sciences and finance experience through their commercial journey.
Invests inHealthcare & Biotech
In its own wordsmedtechbiotechnologylife scienceseisimpacthealthcare
Your fit with Norcliffe Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNorcliffe Capital lists 11 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (91%) and Cybersecurity (9%). 67% of its companies are based in United Kingdom. It invests most often alongside Eos, Mercia Ventures and Convergence Partners.
No funding round on record names Norcliffe Capital yet, so the figures come from its portfolio page.
Round figures show recent activity, not Norcliffe Capital's whole history. Rounds on record name 0 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 96th | 91% in its largest sector |
| Reach | 58th | 3 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 91% | 15% |
| Cybersecurity | 9% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare Norcliffe Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 4D Medicine develops bioabsorbable medical devices and biomaterials | Healthcare & Biotech | Portfolio page | ||
| Afon Technology is a medical device business that develops a non-invasive, continuous blood glucose monitor called Glucowear | Healthcare & Biotech | Portfolio page | ||
| The company is focused on the development of ultra high-performance, low-cost electrochemical biosensing platforms for the point of care medical diagnostics and biosafety testing markets. | Healthcare & Biotech | Portfolio page | ||
| Biosceptre International is a preclinical-stage oncology company developing an adaptor CAR-T platform. | Healthcare & Biotech | Portfolio page | ||
| Dxcover develops a platform for earlier diagnosis of multiple cancers, including brain, pancreatic, and ovarian cancer, using machine learning and light-based technology. | Healthcare & Biotech | Portfolio page | ||
| The company is developing the next generation of therapeutic vaccines for chronic diseases | Healthcare & Biotech | Portfolio page | ||
| Laverock Therapeutics develops advanced therapies through its unique platform technologies | Healthcare & Biotech | Portfolio page | ||
| Oxford Endovascular develops next-generation medical devices for neurovascular disease | Healthcare & Biotech | Portfolio page | ||
| Santersus is a therapeutic apheresis company developing extracorporeal removal of cell-free DNA from patient plasma. | Healthcare & Biotech | Portfolio page | ||
| SMi Systems is a life science company that delivers automated high-throughput single-molecule quantification | Healthcare & Biotech | Portfolio page | ||
| WiFi Securities develops and provides cybersecurity technology to protect businesses and the public from cybercrime | Cybersecurity | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- norcliffe.capital
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Norcliffe Capital's profile as data
Pull Norcliffe Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/norcliffe.capital
# also
GET /v1/firms/norcliffe.capital/portfolio
GET /v1/firms/norcliffe.capital/coinvestors
GET /v1/firms/norcliffe.capital/news